Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) were down 0% during trading on Wednesday . The company traded as low as $17.11 and last traded at $17.98. Approximately 6,549,709 shares traded hands during trading, an increase of 302% from the average daily volume of 1,627,991 shares. The stock had previously closed at $17.98.

A number of analysts have commented on HALO shares. Zacks Investment Research cut shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, September 25th. Piper Jaffray Companies increased their price objective on shares of Halozyme Therapeutics from $26.00 to $29.00 and gave the stock an “overweight” rating in a research note on Monday, October 16th. BMO Capital Markets increased their price objective on shares of Halozyme Therapeutics from $15.00 to $18.00 and gave the stock a “market perform” rating in a research note on Wednesday, November 8th. Canaccord Genuity increased their price objective on shares of Halozyme Therapeutics from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. Finally, Barclays cut shares of Halozyme Therapeutics from an “overweight” rating to a “hold” rating and increased their price objective for the stock from $16.00 to $19.00 in a research note on Wednesday, November 22nd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $19.14.

The company has a quick ratio of 3.37, a current ratio of 3.46 and a debt-to-equity ratio of 2.01. The firm has a market capitalization of $2,530.00, a P/E ratio of -26.25 and a beta of 2.09.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.06 by ($0.04). The firm had revenue of $63.73 million during the quarter, compared to analysts’ expectations of $58.95 million. Halozyme Therapeutics had a negative return on equity of 892.57% and a negative net margin of 53.17%. The business’s revenue for the quarter was up 100.1% on a year-over-year basis. During the same period last year, the company earned ($0.23) earnings per share. equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 0.2 EPS for the current fiscal year.

Large investors have recently modified their holdings of the stock. Rhumbline Advisers boosted its position in shares of Halozyme Therapeutics by 6.6% during the third quarter. Rhumbline Advisers now owns 143,342 shares of the biopharmaceutical company’s stock worth $2,490,000 after acquiring an additional 8,903 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Halozyme Therapeutics by 9.5% during the second quarter. Vanguard Group Inc. now owns 9,595,212 shares of the biopharmaceutical company’s stock worth $123,010,000 after acquiring an additional 831,654 shares during the last quarter. Alps Advisors Inc. boosted its position in shares of Halozyme Therapeutics by 10.7% during the third quarter. Alps Advisors Inc. now owns 139,764 shares of the biopharmaceutical company’s stock worth $2,428,000 after acquiring an additional 13,556 shares during the last quarter. Granite Investment Partners LLC boosted its position in shares of Halozyme Therapeutics by 44.7% during the third quarter. Granite Investment Partners LLC now owns 818,505 shares of the biopharmaceutical company’s stock worth $14,217,000 after acquiring an additional 252,998 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Halozyme Therapeutics by 7.2% during the third quarter. JPMorgan Chase & Co. now owns 2,868,670 shares of the biopharmaceutical company’s stock worth $49,915,000 after acquiring an additional 191,476 shares during the last quarter. Hedge funds and other institutional investors own 84.45% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2018/01/19/halozyme-therapeutics-halo-shares-down-0.html.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.